Disease-specific protein–protein interfaces within chromatin regulatory proteins in DIPG cells

The target 'Disease-specific protein–protein interfaces within chromatin regulatory proteins in DIPG cells' refers to the unique physical contact points between mutant histones and epigenetic complexes that drive Diffuse Intrinsic Pontine Glioma (DIPG). The primary driver of this disease is the H3K27M mutation, which occurs in approximately 80% of cases and involves a lysine-to-methionine substitution in histone H3. This mutation creates a 'poison' interface that binds to and sequesters the Polycomb Repressive Complex 2 (PRC2), specifically inhibiting its catalytic subunit, EZH2. This interaction results in a global loss of H3K27 trimethylation (H3K27me3), a repressive mark essential for maintaining cellular identity, leading to the aberrant activation of oncogenic programs and the stalling of neural differentiation. Therapeutic targeting of these interfaces represents a novel approach to precision medicine, pioneered by companies like TippingPoint Biosciences, which aim to selectively disrupt the transient, pathological complexes unique to the H3K27M-mutant environment. By blocking the interaction between the mutant histone tail and the PRC2 complex, these agents seek to restore the normal epigenetic landscape and promote tumor cell death or differentiation. This strategy is designed to minimize systemic toxicity by exploiting the disease-specific nature of the chromatin architecture in DIPG cells, potentially overcoming the limitations of conventional epigenetic therapies that target catalytic sites shared by healthy tissue.

Other names

H3K27M-PRC2 interfaceH3K27M-EZH2 interactionPathological chromatin interfaces in DIPGMutant histone-chromatin regulator interfacesH3K27M-EED interface

Disruption of the pathological protein-protein interaction between mutant H3K27M histones and chromatin-modifying complexes (such as PRC2) to restore epigenetic homeostasis and H3K27 trimethylation.